Houston biotech startup is one step closer to releasing its marquee drug for the global insulin market, which is projected to break the $90 billion threshold by 2029.

rBIO’s lead biologic drug, R-biolin, aims to disrupt the $90bn insulin market through a biosimilar manufacturing technique that can be massively scaled to yield significant cost savings